Ignite Creation Date:
2024-05-05 @ 4:43 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00300560
Status:
UNKNOWN
Last Update Posted:
2006-05-22
First Post:
2006-03-07
Brief Title:
Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing KPneumoniae or EColi
Sponsor:
Mahidol University
Organization:
Mahidol University
Study Overview
Official Title:
Efficacy and Safety of Colistin for Therapy of Infections Caused by Extended Spectrum Beta-LactamaseESBL Producing Klebsiella Pneumoniae or Escherichia Coli
Status:
UNKNOWN
Status Verified Date:
2006-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In patients with documented ESBL-producing Ecoli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimen
Detailed Description:
In patients with documented ESBL-producing Ecoli and Klebsiella pneumoniae will be allocated to receive colistin or conventional antibiotic regimenThe primary outcome is clinical response and secondary outcomes are microbiological response and adverse events
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None